FDA’s ODAC Rules Unanimously on a Faster Way to Approve Multiple Myeloma Therapies
An FDA advisory committee (ODAC) voted 12-0 today in favor of a major shift in how the agency evaluates new treatments for multiple myeloma. If approved by the FDA, the result will be faster approval of new treatments for multiple myeloma.
12-Apr-2024 5:05 PM EDT
Add to Favorites